PEB - Pacific Edge Ltd

[AndyLP]

Hi Snapiti, would love to see you post the NMP22 sales graph and identify the source.

Here's mine:
With 3.2m revenues this year PEB is around 6 years ahead of Matritech.

Attachment 7107

[skid]

Thanks Andy--Its interesting how their sales increased in the 2nd year and then dropped away--were you following them back in the day?

[skid]

Cheers....

[AndyLP]

skid - not following back in the day, just compiled the numbers recently. sources were:
thebusinesswire.com, thefreelibrary.com

Snap, NMP22 got FDA approval in '96. Did Matritech wait a bit? Why was that

"NEWTON, Mass., July 8, 1996 -- Matritech Inc. (Nasdaq: NMPS; BSE: MPS) announced today that the company's Matritech NMP22(R) Test Kit has been approved for sale in the U.S. by the Food and Drug Administration (FDA) for use in identifying patients at risk for recurrence of bladder cancer.."
http://www.docguide.com/matritechs-n...ved-fda?tsid=5

[AndyLP]

Ah I see, might see if I can find some info on that if I get a chance.

Silicon Investor was a good read for the message boards. http://www.siliconinvestor.com/readm...htype=Previous

[AndyLP]

you truely are a legend....
I do remember that they were concertinaing on Europe 1996-2000 as they considered the market easier to break into.

From a 1998 article with the president of maritech


In Europe we've been selling it for about a year-and-a-half and we've enjoyed sales through distributors in Germany, Spain, Portugal, Italy and are about to sign deals in France and the U.K.


Our objective is to get the thought leaders in urology to use the test, so that we could enjoy that kind of market size in 10-years. Our strategy has been to persuade urologists at such leading centers as Kaiser, The Cleveland Clinic, Johns Hopkins, Massachusetts General Hospital, Boston Medical Center, and a number of the Veterans Administration Hospitals, to use the test this will influence their peers to consider the use of the test as well. It is also noteworthy that the test has been approved not only for the monitoring of bladder cancer patients, but also for screening individuals in Japan.


Looks like PEB are trying nothing knew.

yup those boards are a nice look at sentiment!
I'm not so sure they held off the US market eh. Perhaps they held off selling directly. But looks like they were definitely signing deals to distribute the product in the US back in '99. From the S-3 form back then:

WE DEPEND ON DISTRIBUTORS

We have limited internal marketing and sales resources and personnel. We derive a significant portion of our sales revenue from distribution agreements with two distributors. Konica Corporation has an exclusive right to sell our NMP22 Bladder Cancer Test Kit in Japan. Fisher Diagnostics has a co-exclusive right with us to sell our NMP22 Bladder Cancer Test Kit to hospitals and commercial laboratories in the United States.

Anyways, if that's the case - Pacific Edge would seem to be 'ahead of the curve' wouldn't you agree? Next few announcements will be telling

[MAC]

Apologies for shooting down all your appreciated efforts in a single post.

NMP22 established a capped market with 10 year old tech and with only a single value proposition, it only has a single value proposition because it’s performance is so greatly inferior than that of Cytology. Unfortunate for them, yet they have still prospered within their single limited capped market.

Cxbladder(detect) has up to 10 value propositions because it is the first product to come along that has performance superior to Cytology and has thus opened up many many more new applications and benefits for clinicians.

The market for Cxbladder(detect) is many times over greater than that which NMP22 could ever have been, ten years ago or today, that’s not to say that Pacific Edge will not take their humble capped market off them also though.

A comparison does though serve really very well to highlight just how far ahead Pacific Edge are and just how prosperous they can be compared to Matritech.



A table paints a thousand words, but in summary well, yawn again, <insert nodding off here>

Attachment 7108

[skid]

i dont think they were saying NMP22 was better than CX--They were concerned that CX was still only tracking a similar sales curve--They should be doing alot better shouldnt they? Especially if the market is that much greater.

[MAC]

Not really, it’s just now the beginning,

1. CLIA approval
2. US lab construction
3. Cxbladder(detect) product launch
4. NPN network provider agreements
5. KP demonstration user programme agreement
6. Hiring of initial sales force (12 staff)
7. Opening up of initial geographic sales regions
8. Large insurers commencing reimbursement
9. Commence LUG user programmes
10. Start of revenue ramp up <--- WE ARE HERE
11. Cxbladder(triage) product launch
12. Medicare coverage
13. Commencement of insurer contract agreements
14. KP demonstration user programme results
15. KP contract agreement
16. Profitability
17. Cxbladder(predict) product launch
18. Further HMO user programme initiated
19. Veterans Association coverage
20. Onward and upward to $100M revenues

[skid]

yup those boards are a nice look at sentiment!
I'm not so sure they held off the US market eh. Perhaps they held off selling directly. But looks like they were definitely signing deals to distribute the product in the US back in '99. From the S-3 form back then:

WE DEPEND ON DISTRIBUTORS

We have limited internal marketing and sales resources and personnel. We derive a significant portion of our sales revenue from distribution agreements with two distributors. Konica Corporation has an exclusive right to sell our NMP22 Bladder Cancer Test Kit in Japan. Fisher Diagnostics has a co-exclusive right with us to sell our NMP22 Bladder Cancer Test Kit to hospitals and commercial laboratories in the United States.

Anyways, if that's the case - Pacific Edge would seem to be 'ahead of the curve' wouldn't you agree? Next few announcements will be telling

The next few announcement will certainly be telling --(Or maybe Pierre will get an email reply)